Evidence map›Paper›PMID 37740130›Full record

ArticleCellular and molecular life sciences : CMLS2023

Loss of ORP3 induces aneuploidy and promotes bladder cancer cell invasion through deregulated microtubule and actin dynamics.

Xue Wang, Junnan Liu, Anca Azoitei, Tim Eiseler, Sabine Meessen, Wencheng Jiang, Xi Zheng, Arika W Makori, Markus Eckstein, Arndt Hartmann and 9 more

Open access · hybridAbstract read
In one paragraph

Article in Cellular and molecular life sciences : CMLS, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 10 citations in OpenAlex.

  1. Dna aneuploidy and urothelial carcinoma: A meta-analysis.Current therapeutic research, clinical and experimental · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Role of Oxysterol-Binding Protein Family in Cholesterol Metabolism and Cancer Progression: A Review.Medical science monitor : international medical journal of experimental and clinical research · 2026
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 7 institutions in 4 countries.

Xue Wang *Department of Urology, Ulm University Hospital, Helmholtzstr. 10, 89081, Ulm, Germany.
Junnan Liu *Department of Urology, Ulm University Hospital, Helmholtzstr. 10, 89081, Ulm, Germany.
Anca AzoiteiDepartment of Urology, Ulm University Hospital, Helmholtzstr. 10, 89081, Ulm, Germany.
Tim EiselerDepartment of Internal Medicine I, University Hospital, Ulm, Germany.
Sabine MeessenDepartment of Urology, Ulm University Hospital, Helmholtzstr. 10, 89081, Ulm, Germany.
Wencheng JiangDepartment of Urology, Ulm University Hospital, Helmholtzstr. 10, 89081, Ulm, Germany.
Xi ZhengDepartment of Urology, Ulm University Hospital, Helmholtzstr. 10, 89081, Ulm, Germany.
Arika W MakoriDepartment of Urology, Ulm University Hospital, Helmholtzstr. 10, 89081, Ulm, Germany.
Markus EcksteinInstitute of Pathology, Friedrich-Alexander University, Erlangen, Germany.
Arndt HartmannInstitute of Pathology, Friedrich-Alexander University, Erlangen, Germany.
Stephan StilgenbauerDepartment of Internal Medicine III, University Hospital, Ulm, Germany.
Mohamed ElatiCANTHER, ONCOLille Institute, University of Lille, CNRS UMR 1277, Inserm U9020, 59045, Lille Cedex, France.
Meike HohwielerInstitute of Mol. Oncology and Stem Cell Biology, University Hospital, Ulm, Germany.
Alexander KlegerInstitute of Mol. Oncology and Stem Cell Biology, University Hospital, Ulm, Germany.
Axel JohnDepartment of Urology, Ulm University Hospital, Helmholtzstr. 10, 89081, Ulm, Germany.
Friedemann ZengerlingDepartment of Urology, Ulm University Hospital, Helmholtzstr. 10, 89081, Ulm, Germany.
Felix WezelDepartment of Urology, Ulm University Hospital, Helmholtzstr. 10, 89081, Ulm, Germany.
Christian BolenzDepartment of Urology, Ulm University Hospital, Helmholtzstr. 10, 89081, Ulm, Germany.
Cagatay GünesDepartment of Urology, Ulm University Hospital, Helmholtzstr. 10, 89081, Ulm, Germany. Cagatay.guenes@uniklinik-ulm.de.ORCID http://orcid.org/0000-0003-4301-2223
Helmholtz-Institute Ulm · DEUniversity Hospital Ulm · DEFriedrich-Alexander-Universität Erlangen-Nürnberg · DEMayo Clinic · USCentre National de la Recherche Scientifique · FRHeidelberg University · DENanjing Drum Tower Hospital · CN

Funding

Deutsche Forschungsgemeinschaft EI792/7-1Deutsche Forschungsgemeinschaft GU 569/6-1Wilhelm Sander-Stiftung 2019.038.1
6 · The paper itself

Abstract

We have recently shown that loss of ORP3 leads to aneuploidy induction and promotes tumor formation. However, the specific mechanisms by which ORP3 contributes to ploidy-control and cancer initiation and progression is still unknown. Here, we report that ORP3 is highly expressed in ureter and bladder epithelium while its expression is downregulated in invasive bladder cancer cell lines and during tumor progression, both in human and in mouse bladder cancer. Moreover, we observed an increase in the incidence of N-butyl-N-(4-hydroxybutyl)-nitrosamine (BBN)-induced invasive bladder carcinoma in the tissue-specific Orp3 knockout mice. Experimental data demonstrate that ORP3 protein interacts with γ-tubulin at the centrosomes and with components of actin cytoskeleton. Altering the expression of ORP3 induces aneuploidy and genomic instability in telomerase-immortalized urothelial cells with a stable karyotype and influences the migration and invasive capacity of bladder cancer cell lines. These findings demonstrate a crucial role of ORP3 in ploidy-control and indicate that ORP3 is a bona fide tumor suppressor protein. Of note, the presented data indicate that ORP3 affects both cell invasion and migration as well as genome stability through interactions with cytoskeletal components, providing a molecular link between aneuploidy and cell invasion and migration, two crucial characteristics of metastatic cells.

Indexed as

ActinsUrinary Bladder NeoplasmsAneuploidyAnimalsGenomic InstabilityHumansMiceMicrotubulesNeoplasm InvasivenessOxysterol Binding ProteinsUrinary BladderActinsOSBPL3 protein, humanOsbpl3 protein, mouseOxysterol Binding ProteinsChromosomal imbalanceInvadopodiaMetastasisOSBPL3Spindle orientationUrothelial carcinoma

Identifiers

PMID37740130
PMCPMC10516806
OpenAlexW4386950839

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.